1. Home
  2. OBIO vs ECF Comparison

OBIO vs ECF Comparison

Compare OBIO & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$4.67

Market Cap

237.2M

Sector

Health Care

ML Signal

HOLD

Logo Ellsworth Growth and Income Fund Ltd.

ECF

Ellsworth Growth and Income Fund Ltd.

HOLD

Current Price

$11.91

Market Cap

167.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBIO
ECF
Founded
2017
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
237.2M
167.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBIO
ECF
Price
$4.67
$11.91
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$14.00
N/A
AVG Volume (30 Days)
333.5K
57.7K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
6.42%
EPS Growth
N/A
N/A
EPS
N/A
0.46
Revenue
$2,818,000.00
N/A
Revenue This Year
$36.43
N/A
Revenue Next Year
$2.56
N/A
P/E Ratio
N/A
$17.61
Revenue Growth
6.46
N/A
52 Week Low
$2.20
$7.02
52 Week High
$6.30
$8.91

Technical Indicators

Market Signals
Indicator
OBIO
ECF
Relative Strength Index (RSI) 54.93 54.28
Support Level $4.19 $11.80
Resistance Level $5.42 $11.93
Average True Range (ATR) 0.35 0.19
MACD -0.09 0.05
Stochastic Oscillator 40.82 90.38

Price Performance

Historical Comparison
OBIO
ECF

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

Share on Social Networks: